PeerVoice Brain & Behaviour Audio

Silvia Messina, MD, DPhil / Michael Levy, MD, PhD - Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) or Something Else? How to Tell the Difference

Georgios Tsivgoulis, MD, PhD, MSc - Navigating the Latest Evidence Surrounding Current and Emerging Strategies for Secondary Stroke Prevention

Mike Sharma, MD, MSc, FRCPC - Deepening the Dialogue on the Latest Data for Factor XIa Inhibition: Is It Time to Shift the Paradigm in Secondary Stroke Prevention?

Xin Cheng, MD, PhD - Seeking Solutions in Secondary Stroke Prevention: The Latest Inquiries and Insights on Factor XIa Inhibition

Caterina Garone, MD, PhD - From Clinical Clues to a Confirmatory Diagnosis: Recognising Thymidine Kinase 2 Deficiency Across the Age Spectrum

Ashkan Shoamanesh, MD, FRCPC - Turning Pathophysiologic Promise Into Evidence-Based Potential: Are Factor XIa Inhibitors Ready for Prime Time in Secondary Stroke Prevention?

Sara Mariotto, MD, PhD - Beyond Myasthenia Gravis: What Are We Learning About FcRn Inhibitors in Other Rare Neuroimmunological Disorders?

Colin Russell, PhD / John Watkins, MBBCh, BSc - A Shot in the Arm: Leveraging Combination Vaccines for Global Health Impact

James F. Howard Jr, MD - Direct From San Francisco: Emerging Data and Expert Perspectives on Targeted Therapies for gMG

Mike Sharma, MD, MSc, FRCPC - Challenging the Status Quo in Secondary Stroke Prevention: Current Perspectives on the Potential of Factor XIa Inhibition

Patrick Vermersch, MD, PhD - Stripped Back: CNS Inflammation and the Potential for Meaningful Therapeutic Progress in Non-Relapsing Forms of Multiple Sclerosis

Bernhard Suter, MD - Rett Syndrome Uncovered: An International Exchange on Recognition, Monitoring, and Emerging Therapies

Richard B. Lipton, MD - Overcoming the Disconnects Between Recommendations and Reality in Acute Migraine Treatment: Patient and Provider Perspectives on Communication and Collaboration

Richard A. Lewis, MD - Navigating the Evolving CIDP Treatment Landscape: Expert Perspectives on the Therapeutic Potential of Complement Inhibition

Heinz Wiendl, MD - Neurology Updates From the European Meeting in Helsinki (June 2025)

Saiju Jacob, MD, DPhil, FRCP, FAAN - The Value of Disease Control in gMG: The Latest Data Evaluating Patient Needs and Treatment Outcomes as They Emerge From Helsinki

Angela Kay Fitch, MD, FACP, MFOMA - Separating Signal From Noise: Overcoming the Challenges of Obesity Management in Real-World Clinical Practice

Laurent Servais, MD, PhD - Eligible for Gene Therapy? The Complexity and Therapeutic Implications of Anti-AAV Antibodies

Ashkan Shoamanesh, MD, FRCPC - Can We Find a New Way Forward in Secondary Stroke Prevention? Exploring the Rationale and Potential Roles for Factor XIa Inhibition

Luis Querol, MD, PhD - 2025 Congress Highlights From Edinburgh, Scotland: Breaking Down the Data Driving Novel Therapeutic Developments in CIDP

Heinz Wiendl, MD - Myasthenia Gravis Under the Microscope: 2025 Insights From The Hague

Nicholas J. Silvestri, MD, FAAN - From Established to Emerging Therapies: Expert Perspectives on the Latest Evidence Base on FcRn Inhibitors for gMG

Mike Sharma, MD, MSc, FRCPC - Can We Set a New Standard of Care for Secondary Stroke Prevention? Evaluating Current Gaps and Future Goals

Gavin Giovannoni, MBBCh, PhD - Navigating and Pioneering High-Efficacy DMT Strategies: Optimizing Patient Outcomes in Multiple Sclerosis

James F. Howard Jr, MD - Beyond FcRn and Complement Inhibitors: Why We Need Novel Treatment Options for Generalized Myasthenia Gravis